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The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent
signalling network by targeting the ubiquitin system
Sam STRICKSON*, David G. CAMPBELL*, Christoph H. EMMERICH*, Axel KNEBEL†, Lorna PLATER*, Maria Stella RITORTO*,
Natalia SHPIRO* and Philip COHEN*†1
*MRC Protein Phosphorylation Unit, Sir James Black Centre, University of Dundee, Dundee DD1 5EH, U.K., and †Scottish Institute for Cell Signaling, Sir James Black Centre, University
of Dundee, Dundee DD1 5EH, U.K.
The compound BAY 11-7082 inhibits IκBα [inhibitor of NF-
κB (nuclear factor κB)α] phosphorylation in cells and has been
used to implicate the canonical IKKs (IκB kinases) and NF-κB
in >350 publications. In the present study we report that BAY
11-7082 does not inhibit the IKKs, but suppresses their activation
in LPS (lipopolysaccharide)-stimulated RAW macrophages and
IL (interleukin)-1-stimulated IL-1R (IL-1 receptor) HEK (human
embryonic kidney)-293 cells. BAY 11-7082 exerts these effects
by inactivating the E2-conjugating enzymes Ubc (ubiquitin
conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear
ubiquitin assembly complex), thereby preventing the formation
of Lys63-linked and linear polyubiquitin chains. BAY 11-7082
prevents ubiquitin conjugation to Ubc13 and UbcH7 by forming
a covalent adduct with their reactive cysteine residues via Michael
addition at the C3 atom of BAY 11-7082, followed by the release
of 4-methylbenzene-sulfinic acid. BAY 11-7082 stimulated Lys48-
linked polyubiquitin chain formation in cells and protected HIF1α
(hypoxia-inducible factor 1α) from proteasomal degradation,
suggesting that it inhibits the proteasome. The results of the
present study indicate that the anti-inflammatory effects of BAY
11-7082, its ability to induce B-cell lymphoma and leukaemic
T-cell death and to prevent the recruitment of proteins to sites
of DNA damage are exerted via inhibition of components of the
ubiquitin system and not by inhibiting NF-κB.
Key words: lymphoma, linear ubiquitin assembly complex
(LUBAC), myeloid differentiation factor 88 (MyD88), nuclear
factor κB (NF-κB), proteasome, ubiquitin conjugating 13
(Ubc13).
INTRODUCTION
MyD88 (myeloid differentiation factor 88) is an adaptor protein
that plays an essential role in the signalling networks that are
activated by PAMPs (pathogen-associated molecular patterns), as
well as by IL (interleukin)-1, IL-18 and IL-33 [1]. The interaction
of these agonists with their receptors induces the recruit-
ment of MyD88 and members of the IRAK (IL-receptor-
associated kinase) family of protein kinases to form a structure
known as the Myddosome [2,3]. The activation of the IRAKs
is followed by the activation of TRAF (tumour-necrosis-factor-
receptor-associated factor) 6, an E3 ligase that facilitates the
formation of K63-pUb [Lys63-linked pUb (polyubiquitin)] chains
in the presence of the E2 conjugating complex Ubc (ubiquitin
conjugating) 13-Uev1a [4]. Linear-pUb chains formed by the
action of the E3 ligase LUBAC (linear ubiquitin assembly
complex) also appear to play a key role in this pathway [5,6].
The K63-pUb chains have been proposed to be essential for the
activation of the protein kinase TAK1 (transforming growth
factor β-activated kinase 1) [7,8] and linear pUb chains for
the activation of the canonical IKK {IκB [inhibitor of NF-κB
(nuclear factor κB)] kinase} complex [9]. The interaction of K63-
pUb chains with the TAB (TAK1-binding protein) 2 and TAB3
components of the TAK1 complex [10,11] is thought to induce
a conformational change that permits the auto-activation of the
TAK1 catalytic subunit [7,8]. Similarly, the binding of K63-pUb
[12,13] and/or linear-pUb chains [14,15] to the NEMO (NF-κB
essential modifier) component of the canonical IKK complex
is believed to induce conformational changes that facilitate the
activation of the IKKα and IKKβ components of this complex
by TAK1. TAK1 also activates MAPK (mitogen-activated protein
kinase) kinases that switch on p38 MAPKs and JNKs (c-Jun
N-terminal kinases) [16,17], whereas the canonical IKK complex
has multiple downstream targets, including not only the inhibitory
IκBα component of the transcription factor NF-κB, but also the
inhibitory p105/NF-κB1 component of the Tpl2 (tumour progres-
sion locus 2) kinase. The IKK-catalysed phosphorylation of these
proteins leads to the activation of NF-κB and the MAPKs ERK
(extracellular-signal-regulated kinase) 1 and ERK2 respectively
[18,19]. Together the signalling networks initiated by PAMPs
ultimately induce the production of many inflammatory mediators
that are deployed to fight infection by invading microbes.
Recently, mutations in MyD88 that cause the constitutive
activation of the MyD88 signalling pathway have been identified
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kidney; HIF1α, hypoxia-inducible factor 1α; HOIP, haem-oxidized IRP2 ligase-1-interacting protein; HRMS, high-resolution mass spectra; HTLV-1, human
T-cell lymphotropic virus 1; IL, interleukin; IL-1R, IL-1 receptor; IRAK, IL-receptor-associated kinase; IκB, inhibitor of NF-κB; IKK, IκB kinase; JNK, c-Jun
N-terminal kinase; K48-pUb, Lys48-linked polyubiquitin; K63-pUb, Lys63-linked polyubiquitin; LPS, lipopolysaccharide; LUBAC, linear ubiquitin assembly
complex; MALDI–TOF, matrix-assisted laser-desorption ionization–time-of-flight; MAPK, mitogen-activated protein kinase; MS/MS, tandem MS; MyD88,
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as a major cause of the activated B-cell subtype of DLBCL (diffuse
large B-cell lymphoma), one of the least curable forms of this
blood cancer. One MyD88 mutation in particular, in which Leu265
is changed to a proline residue, accounts for approximately a
third of all cases of DLBCL [20]. These findings raised the
question of whether inhibitors of protein kinases that are activated
downstream of MyD88, when used alone or in combination, might
prevent the proliferation of these lymphoma cells or even induce
their destruction. We therefore tested a number of compounds
reported to inhibit the protein kinases in this pathway that are
known to suppress inflammatory mediator production. However,
only BAY 11-7082 and the closely related BAY 11-7085 induced
the death of a B-cell lymphoma line carrying the MyD88[L265P]
mutation. BAY 11-7082 has been reported to inhibit the phos-
phorylation of IκBα in cells and for this reason has been used in
over 350 published research papers to implicate the canonical IKK
complex and NF-κB in many cellular events. However, we found
that other inhibitors of the canonical IKK complex or its activator
TAK1 did not induce the apoptosis of the B-cell lymphoma carry-
ing the L265P mutation. This led us to discover that BAY 11-7082
is not a direct inhibitor of the canonical IKK complex, but prevents
its activation by targeting components of the ubiquitin system.
These include Ubc13, the E2 conjugating enzyme that directs the
formation of K63-pUb chains, as well as UbcH7 and LUBAC,
which generate linear pUb chains. BAY 11-7082 also stimulates
the production of K48-pUb (Lys48-linked polyubiquitin) chains in
cells, probably by inhibiting the proteasome.
EXPERIMENTAL
Materials
NG25 [21], BI 605906 [22], MLN4924 [23] and NSC697923
[24] were synthesized as described previously. BAY 11-7082
and BAY 11-7085 were purchased from Merck-Millipore, 5Z-7-
oxozeaenol [25] was from BioAustralis, LPS (lipopolysaccharide;
Escherichia coli 055:B5) was from Alexis Biochemicals (cata-
logue number ALX-581-001), Resazurin and MG132 were from
Sigma and N-acetyl cysteine was from Tokyo Chemical Industry.
Proteins and antibodies
Human IL-1β was expressed as a glutathione transferase fusion
protein in E. coli and cleaved with PreScission proteinase to
release IL-1β[117–268], which was purified by gel filtration
on Superdex 200. The human UBE1 (ubiquitin-activating
enzyme), the E2 ubiquitin-conjugating enzyme Ubc13 (also called
UBE2N) and UbcH7 (also called UBE2L3) were expressed
as His6-tagged fusion proteins followed by a PreScission
proteinase cleavage tag. Each protein therefore started with
the sequence MGSSHHHHHHSSGLEVLFQGPGS, followed
by the amino acid residue after the initiating methionine
residue of each protein. The E2scanTMKit was purchased
from Ubiquigent Ltd. Immunoprecipitating antibodies against
bacterially expressed human HOIP (haem-oxidized IRP2 ligase-
1-interacting protein) (S174D, 3rd bleed) and human IRAK4
(S522C, 3rd bleed) were raised in sheep at Diagnostics Scotland
and the antisera were affinity purified on antigen–agarose columns
by the Antibody Production Team (Division of Signal Trans-
duction Therapy, Medical Research Council Protein Phosphoryla-
tion Unit, University of Dundee, Dundee, U.K.). Antibodies
that recognize ubiquitin were purchased from Dako (catalogue
number Z0458) and Enzo Life Sciences (catalogue number BML-
PW8810-0500). Antibodies that recognize GFP (green fluorescent
protein) (Abcam), K63-pUb chains (eBioscience), K48-pUb
chains, IRAK4 and histone γ H2AX (Merck-Millipore) were
purchased from the sources indicated. Antibodies that recognize
IKKβ phosphorylated at Ser177 and Ser181, p105 phosphorylated at
Ser933, TBK1 (TRAF-associated NF-κB activator-binding kinase
1) phosphorylated at Ser172, IRAK4 phosphorylated at Thr345 and
Ser346, p38α MAPK phosphorylated at its Thr-Gly-Tyr motif,
and all forms of IκBα and GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) were purchased from Cell Signaling Technology.
The antibody recognizing HIF1α (hypoxia-inducible factor 1α)
was from R&D Systems, whereas the antibodies recognizing
Cullin 2 and JNK phosphorylated at its Thr-Pro-Tyr motif were
from Invitrogen. Secondary antibodies with fluorophores 488 and
594 for the detection of GFP and γ H2AX respectively, were
obtained from Alexa Fluor.
Cell culture
HBL-1 cells (provided by Louis Staudt, National Cancer
Institute, Bethesda, MD, U.S.A.) were cultured in RPMI
medium supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and antibiotics (100 units/ml penicillin and 100 μg/ml
streptomycin). HEK (human embryonic kidney)-293 cells stably
expressing IL-1R (IL-1 receptor) (hereafter called IL-1R cells)
(provided by Xiaoxia Li and George Stark, Case Western
Reserve University, Cleveland, OH, U.S.A.) and the RAW
264.7 macrophage cell line (hereafter called RAW cells)
were maintained in DMEM (Dulbecco’s modified Eagle’s
medium) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and antibiotics (100 units/ml penicillin and 100 μg/ml
streptomycin). U2OS cells were cultured in McCoy’s 5A growth
medium supplemented as described for DMEM. U2OS cells were
transfected using LipofectamineTM (Invitrogen) according to the
manufacturer’s instructions. All cells were cultured at 37 ◦C in a
10% CO2 humidified atmosphere.
Cell stimulation and cell lysis
All cells were incubated for 1 h with or without inhibitors
prior to stimulation with agonists. IL-1R cells were stimulated
with 0.5 ng/ml IL-1β and RAW cells with 100 ng/ml LPS.
Cells were rinsed in ice-cold PBS and extracted in lysis buffer
[50 mM Tris/HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1%
(v/v) Triton X-100, 1 mM sodium orthovanadate, 50 mM NaF,
5 mM sodium pyrophosphate, 0.27 M sucrose, 10 mM sodium
2-glycerophosphate, 0.2 mM PMSF and 1 mM benzamidine].
For the experiments in which pUb chains were captured on
Halo-NEMO, or in which the expression of HIF1α was studied,
the lysis buffer included 100 mM iodoacetamide to inactivate
deubiquitylases. Cell lysates were clarified by centrifugation
(14000 g; 30 min; 4 ◦C) the supernatants (cell extracts) were
removed and protein concentrations were determined by the
Bradford procedure.
Immunoblotting
Protein samples were denatured in LDS (lithium dodecyl sulfate)
or SDS and subjected to SDS/PAGE on 4–12% gradient
polyacrylamide gels (NuPAGE; Invitrogen). After transfer to
PVDF membranes and blocking with 5% (w/v) non-fat dried
skimmed milk powder in 50 mM Tris/HCl, pH 7.5, 0.15 M NaCl
and 0.1% Tween 20, proteins were visualized by immunoblotting
using the ECL (enhanced chemiluminescence) system (GE
Healthcare).
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Cell proliferation assays
HBL-1 cells were seeded into a black 96-well plate at 25 000
cells per well in a total volume of 0.1 ml of RPMI medium. The
pharmacological inhibitors (at 10 mM in DMSO) were diluted
appropriately in RPMI medium and 50 μl was added to each well.
All assays were performed in triplicate. To assess cell viability and
proliferation, 15 μl of a 0.11 mg/ml solution of resazurin in water
was then added to each well. The solution was incubated for 3 h
at 37 ◦C before reading the emitted fluorescence at 590 nm after
excitation at 540 nm on a SpectraMax M2 Fluorescence Plate
Reader. A blank reaction in which 0.15 ml of RPMI medium
was incubated with 15 μl of 0.11 mg/ml rezaurin and used as the
control.
Preparation of Halo-NEMO and NEMO ‘pull-down’ assays
The pUb-binding protein NEMO was expressed in E. coli
as a Halo-tagged protein. The cells were lysed in 50 mM
Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA,
0.1% 2-mercaptoethanol, 1 mM benzamidine and 0.2 mM PMSF,
sonicated and the lysate was centrifuged to remove cell debris.
The supernatant was coupled to the HaloLink resin (Promega) by
incubation for 5 h at 4 ◦C as described by the manufacturer. The
HaloLink resin (1.0 ml) was added to 10 ml of cleared lysate.
The resin was washed with 50 mM Tris/HCl, pH 7.5, 0.5 M
NaCl, 0.1 mM EDTA, 270 mM sucrose, 0.03% Brij 35, 0.1%
2-mercaptoethanol, 0.2 mM PMSF and 1 mM benzamidine and
stored at 4 ◦C. To capture K63-pUb and linear-pUb chains from
cell extracts, 3–6 mg of cell extract protein was incubated for
16 h at 4 ◦C with Halo-NEMO beads (30 μl packed volume). The
beads were washed three times with 1 ml of lysis buffer containing
500 mM NaCl and once with 1 ml of 10 mM Tris/HCl, pH 8.0.
K63-pUb chains captured by the Halo-NEMO were released by
denaturation in SDS and identified by immunoblotting.
E1 and E2 ubiquitin-loading assays
UBE1 (0.17 μM) in 22.5 μl of 20 mM Hepes, pH 7.5, containing
10 μM ubiquitin was incubated for 45 min at 21 ◦C with 1 μl of
DMSO or 1 μl of BAY 11-7082 in DMSO. A 2.5 μl solution
of 10 mM magnesium acetate and 0.2 mM ATP was added,
incubated for 10 min at 30 ◦C, and the reactions were terminated
by the addition of 2.5 μl of 10% (w/v) SDS and heating for
6 min at 75 ◦C. The samples were subjected to SDS/PAGE in the
absence of any thiol. The gels were stained for 1 h with Coomassie
Instant Blue and destained by washing with water. The loading
of ubiquitin to E2 conjugating enzymes was carried out in an
identical manner, except that UBE1 (0.17 μM) was mixed with
Ubc13 (2.4 μM) or UbcH7 (2.9 μM) prior to incubation with BAY
11-7082.
Assay of the endogenous LUBAC E3 ligase
Anti-HOIP antibody (1 μg) was incubated for 2 h at 4 ◦C with
Protein G–Sepharose (10 μl packed beads) in 0.5 ml of 50 mM
Tris/HCl, pH 7.5, and 0.2% Triton X-100. The beads were
washed three times with cell lysis buffer and incubated for
16 h at 4 ◦C with 1 mg of cell extract protein. The beads were
collected by brief centrifugation, washed three times with 0.5 ml
of 50 mM Tris/HCl, pH 7.5, 1% (v/v) Triton X-100, 0.05% 2-
mercaptoethanol and 0.2 M NaCl and once with 50 mM Tris/HCl,
pH 7.5, and 5 mM MgCl2. The immunoprecipitated LUBAC
complex was resuspended in 20 μl of 20 mM Tris/HCl, pH 7.5,
2 mM DTT, 0.1 μM UBE1, 0.4 μM UbcH7, 10 μM ubiquitin,
5 mM MgCl2 and 2 mM ATP. After incubation for 1 h at 30 ◦C,
reactions were stopped by denaturation in SDS. The formation
of linear-pUb chains was analysed by immunoblotting with an
anti-ubiquitin antibody.
Measurement of the molecular mass of Ubc13 by MALDI–TOF
(matrix-assisted laser-desorption ionization–time-of-flight)-MS
Ubc13 (2.6 μM) was incubated for 30 min at 21 ◦C without
or with 10 μM BAY 11-7082 in 25 mM Hepes, pH 7.5, and
then exchanged into 5 mM Tris/HCl, pH 7.5. An aliquot of
the reaction (2 μl) was added to 2 μl of the matrix (2,5-
dihydroxyacetophenone) and 2 μl of 2% (v/v) trifluoroacetic acid
was added before spotting 1 μl of the sample on to a steel target.
The analysis was performed manually in reflector positive mode
using an UltrafleXtreme (Bruker Daltonics) MALDI–TOF mass
spectrometer. For external calibration, two mono-isotopic masses
were used: cytochrome c [M + H]+ (12 361 Da) and myoglobin
[M + H]+ (16 952 Da).
Edman sequencing
This was performed on an Applied Biosystems ProCis e494c
sequencer according to the manufacturer’s instructions.
Mass spectrometric analysis of tryptic peptides
Tryptic peptide analysis using LC (liquid crystallography)-
MS/MS (tandem MS) was performed on an Easy nLC
HPLC coupled to an LTQ-Orbitrap Classic (Thermo) and data
was analysed using the Mascot search program (http://www.
matrixscience.com). Peptides were analysed for modification by
BAY 11-7082 by the addition of a cysteine-specific modification
of + C(3) H(1) N(1) ( + 51.011 Da) to Mascot. Gluconylation,
+ C(6) H(10) O(6) ( + 178.048 Da), was a standard Mascot
modification.
Reaction of N-acetyl cysteine with BAY 11-7082 and analysis of the
products of the reaction by NMR spectroscopy and MS
A solution of BAY 11-7082 (0.0037 g, 0.018 mmol) in DMSO
(0.2 ml) was added at 20 ◦C to a solution of N-acetyl cysteine
(0.003 g, 0.018 mmol) and Tris (2-carboxyethyl) phosphine
hydrochloride (0.011 g, 0.038 mmol) in 1 M phosphate buffer,
pH 8.5 (1 ml). The reaction was vortex-mixed for 2 min,
allowed to stand for 15 min, diluted with 1 ml of 5:95
acetonitrile/water (0.1% formic acid) and applied to a Waters
Xbridge 19 μm×100 μm diameter, 5 μm particle size C18
column. The column was developed with a gradient from
5% to 95% acetonitrile in water (0.1% formic acid) at a
flow rate of 25 ml/min. The appropriate fractions were pooled
and concentrated, and the structures of the products (R,E)-
2-acetamido-3-[(2-cyanovinyl)thio] propanoic acid (Compound
1) (2.0 mg, 0.009 mmol, 50%) and 4-methylbenzene-sulfinic
acid (Compound 2) (0.002 g, 0.0128 mmol, 71%) deduced
from NMR spectra were recorded on a Bruker AVANCE II
500 spectrometer. HRMS (high-resolution mass spectra) were
obtained on a microTOF Bruker Daltonics instrument.
Immunofluorescence and induction of DNA damage
Cells plated on sterile coverslips were fixed for 10 min at 21 ◦C
using 4% paraformaldehyde. Soluble proteins were removed
before fixation by extraction for 5 min in ice-cold 10 mM Pipes,
pH 7.0, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM
EGTA and 0.5% Triton X-100. Cells were permeabilized for
20 min at 21 ◦C with PBS containing 0.2% Triton X-100, washed
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Figure 1 BAY 11-7082 and BAY 11-7085, but not other inhibitors of the
activity and activation of the canonical IKK complex, induce HBL-1 cell
death
HBL-1 cells were incubated without any inhibitor () or in the presence of the TAK1 inhibitors
5Z-7-oxozeaenol (1 μM, ) and NG25 (1 μM, ), the IKKβ inhibitor BI605906 (10 μM,
), BAY 11-7082 (3 μM,) or BAY 11–7085 (3 μM,). Values are means +− S.D. for three
experiments each performed in triplicate.
several times in PBS and then incubated in blocking solution (PBS
containing 5% donkey serum, 0.1% fish skin gelatin and 0.05%
Tween 20). Cover slips were incubated for 1 h at 21 ◦C with
primary antibodies in blocking solution, then washed in PBS and
incubated for 1.5 h with the fluorophore-conjugated secondary
antibodies. The nuclei were stained for 30 min with DAPI (4′,6-
diamidino-2-phenylindole) before coverslips were mounted on to
glass slides. Slides were viewed using a Nikon eclipse Ti inverted
microscope. Exposure of the cells to ionizing radiation was carried
out at 2 Grays with a 137Cs radiation source.
RESULTS
BAY 11-7082 and BAY 11-7085, but not other inhibitors of IKK
activity, induce the death of HBL-1 lymphoma cells carrying the
MyD88[L265P] mutation
We examined whether compounds reported to inhibit the activity
or activation of the canonical IKK complex also inhibited
the proliferation of HBL-1 lymphoma cells expressing the
MyD88[L265P] mutation. BI605906, a potent and selective
inhibitor of IKKβ [22] and two structurally unrelated inhibitors
of TAK1, 5Z-7-oxozeaenol [25] and NG25 [21], only slowed
cell growth modestly (Figure 1). We were therefore surprised
to find that BAY 11-7082, another compound reported to inhibit
the phosphorylation of IκBα and activation of NF-κB, induced the
death of HBL-1 cells (Figure 1). BAY 11-7085, a closely related
molecule, had a similar effect (Figure 1). Since neither the IKKβ
inhibitor BI605906 nor the TAK1 inhibitors that prevent the
MyD88-dependent activation of the IKK complex in fibroblasts or
macrophages had this effect [22,26], it seemed that BAY 11-7082
must be inducing HBL-1 cell death by another mechanism and
prompted us to explore which proteins BAY 11-7082 and BAY
11-7085 might be targeting.
BAY 11-7082 does not inhibit the canonical IKK complex or the
IKK-related kinases in vitro, but inhibits their activation by LPS
and IL-1 in RAW and IL-1R cells respectively
We found that BAY 11-7082 did not inhibit IKKα, IKKβ
and the IKK-related kinases TBK1 and IKKε when assayed at
10 μM in vitro (Supplementary Table S1 at http://www.biochemj.
org/bj/451/bj4510427add.htm). Nevertheless, BAY 11-7082
completely suppressed the LPS-stimulated (Figure 2A) and
Figure 2 BAY 11-7082 suppresses the activation of IKK family members
and JNK
(A) Murine RAW 264.7 macrophages were incubated for 1 h with the indicated concentrations
of BAY 11-7082 and then stimulated for 15 min with 100 ng/ml LPS. The cells were lysed and
aliquots of the cell extract (20 μg of protein) were denatured in SDS, subjected to SDS/PAGE,
and immunoblotted with antibodies that recognize the active phosphorylated form of IKKβ ,
the IKKβ substrate p105 phosphorylated at Ser933 and all forms of IκBα and GAPDH. (B)
Same as (A), except that human IL-1R cells were used and the cells stimulated for 15 min with
0.5 ng/ml IL-1β . (C) Same as (B), except that IL-1R cells were immunoblotted with antibodies
that recognize TBK1 phosphorylated at Ser172 and an antibody that recognizes all forms of
TBK1. (D) As in (A), except that the RAW macrophages were incubated for 1 h with 15 μM BAY
11-7082, then stimulated with LPS and the gels were immunoblotted for JNK phosphorylated
at Thr183 and Tyr185, p38 MAPK phosphorylated at Thr180 and Tyr182 and GAPDH. (E) As in (D),
except that IL-1R cells were stimulated with 0.5 ng/ml IL-1. p-, phospho-.
IL-1-stimulated (Figure 2B) phosphorylation of the activation
loop of IKKβ. As a consequence, the phosphorylation of its
substrate p105/NF-κB1 and the degradation of IκBα (which is
triggered by the IKK-catalysed phosphorylation of IκBα) were
also prevented. The protein kinase TAK1 was partially inhibited
by BAY 11-7082 in vitro (Supplementary Table S1), but BAY 11-
7082 also suppressed the IL-1-stimulated activation of TBK1 in
IL-1R cells (Figure 2C), which is dependent upon the expression
of TRAF6, but independent of the expression or catalytic
activity of TAK1 [22]. BAY 11-7082 additionally prevented the
LPS- or IL-1-stimulated activation of JNK in RAW or IL-1R
c© The Authors Journal compilation c© 2013 Biochemical Society
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Figure 3 BAY 11-7082 does not affect the LPS-stimulated autophosphoryla-
tion of IRAK4
(A) Murine RAW 264.7 macrophages were incubated for 1 h without ( − ) or with ( + ) 15 μM
BAY 11-7082 and then stimulated for the times indicated with 100 ng/ml LPS. The cells
were lysed and aliquots of the cell extract (20 μg of protein) were subjected to SDS/PAGE
and immunoblotting (bottom three panels) with the antibodies used in Figure 2. IRAK4 was
immunoprecipitated (IP) from 2 mg of cell extract protein using 2 μg of anti-IRAK4 antibody
using the procedure used to immunoprecipitate HOIP (see the Experimental section). The
immunoprecipitates were denatured in SDS, subjected to SDS/PAGE and immunoblotted with
an antibody that recognizes IRAK4 phosphorylated at Thr346 and Ser346 (p-IRAK4) and an
antibody that recognizes all forms of IRAK4. (B) Same as (A), except that IL-R cells were used
and stimulated with 0.5 ng/ml IL-1. p-, phospho-.
cells. BAY 11-7082 did not inhibit IRAK4 or IRAK1 in vitro
(Supplementary Table S1), which are the most ‘upstream’ protein
kinases in the MyD88 signalling network, and nor did it prevent
the autophosphorylation of IRAK4 induced by LPS in RAW
macrophages (Figure 3A) or IL-1 in IL-1R cells (Figure 3B).
BAY 11-7082 induced near-maximal activation of p38α MAPK
in unstimulated cells that could not be enhanced further by
stimulation with LPS or IL-1 (Figures 2D and 2E), suggesting
that this compound induces the activation of one or more stress-
response pathways that are known to activate p38α MAPK.
BAY 11-7082 inhibits the formation of K63-pUb chains
The experiments described above indicated that BAY 11-7082
exerted its effects on the MyD88-dependent signalling network
‘downstream’ of the IRAK family of protein kinases, but
‘upstream’ of IKKα, IKKβ and TBK1, which suggested that
it might be affecting the ability of TRAF6 and/or other E3
ubiquitin ligases to generate K63-pUb chains. To investigate this
possibility, we used NEMO immobilized on Halo beads to capture
the K63-pUb chains formed upon stimulation with LPS or IL-1
[27]. These experiments showed that BAY 11-7082 prevented
the LPS- or IL-1-stimulated formation of K63-pUb chains at
concentrations similar to those that suppressed the activation of
IKKβ (Figures 4A and 4B).
BAY 11-7082 inhibits the recruitment of proteins to sites of DNA
damage
K63-pUb chains are not just involved in IL-1 and TLR (toll-
like receptor)-stimulated signalling networks, but also in other
cellular events, including the recruitment of components of the
DNA-repair machinery to sites of DNA damage [28], including
the RAP80 component of the BRCA1 (breast cancer early-
onset 1) complex [29]. The recruitment of RAP80 to DNA
damage-induced sub-nuclear ‘foci’ has been shown to require
Ubc13 [29]. If BAY 11-7082 inactivates Ubc13, we reasoned
that this compound should also suppress the recruitment of
RAP80 to DNA damage foci. When U2OS cells were exposed
to ionizing radiation, GFP–RAP80 became localized to sites of
DNA damage (Figure 4Ci), which was prevented by BAY 11-
7082 (Figure 4Cii). In contrast, in cells that were not exposed to
ionizing radiation (Figure 4Ciii), RAP80 did not form foci in the
absence (Figure 4Ciii) or presence (Figure 4Civ) of BAY 11-7082.
As a control experiment, the formation of the phosphorylated
form of histone H2AX (γ H2AX) at sites of DNA damage
(Figure 4Cv), which is not dependent on the formation of K63-
pUb chains [28], was studied. As expected, γ H2AX foci were
little affected by BAY 11-7082 (Figure 4Cvi). In contrast, cells
that had not been exposed to ionizing radiation did not form foci
and so no γ H2AX foci were observed (Figure 4Cvii). However,
some γ H2AX foci were observed in cells that had not been
exposed to ionizing radiation, but had been incubated with BAY
11-7082 (Figure 4Cviii), probably because the inhibition of K63-
pUb chain formation by BAY 11-7082 prevents the repair of
DNA damage that occurs spontaneously in cells at a low rate.
Figures 4(Cix)–4(Cxii) are control experiments showing DAPI
staining and merged images of Figures 4(Ci)–4(Civ) with 4(Cv)–
4C(viii).
BAY 11-7082 inhibits the loading of ubiquitin on to E2
conjugating enzymes
The generation of pUb chains is initiated by the MgATP-
dependent transfer of ubiquitin to a cysteine residue on the
ubiquitin-activating enzyme UBE1, which is followed by transfer
of the ubiquitin to a cysteine residue on E2 conjugating enzymes.
It was therefore possible that BAY 11-7082 might be suppressing
K63-pUb chain formation by preventing the conjugation of
ubiquitin to UBE1 or the transfer of ubiquitin from UBE1 to
the active-site cysteine residue on an E2. To examine these
possibilities we initially used Ubc13, which directs the formation
of K63-pUb chains by TRAF6 [4] and other E3 ubiquitin ligases
[30] when it is complexed to the inactive ‘pseudo-E2’ Uev1a.
These experiments demonstrated that BAY 11-7082 did not affect
the loading of ubiquitin to UBE1 under the conditions tested
(Figure 5A), but completely blocked the transfer of ubiquitin
from UBE1 to Ubc13 (Figure 5B). BAY 11-7082 also prevented
the transfer of ubiquitin from UBE1 to UbcH7 (Figure 5C),
which is the E2 thought to act with RBR (RING-between-
RING) E3 ligases [31] such as LUBAC (see below). BAY 11-
7085 similarly prevented the conjugation of ubiquitin to Ubc13
and UbcH7, although it was slightly less potent than BAY 11-
7082 (results not shown). These findings led us to test whether
BAY 11-7082 affected the loading of other E2 conjugating
enzymes that accept ubiquitin from UBE1. We found that 24
E2 conjugating enzymes were inactivated by incubation with
10 μM BAY 11-7082 in vitro, but the conjugation of ubiquitin
to UBE2G1 and UBE2H was only partially reduced by this
concentration of BAY 11-7082 (Supplementary Figure S1A at
http://www.biochemj.org/bj/451/bj4510427add.htm).
The mechanism by which BAY 11-7082 inhibits Ubc13 and UbcH7
The Ubc13 preparation used in these experiments (see the
Experimental section) was expressed in E. coli as a His6-tagged
protein. When this preparation was subjected to MALDI–TOF-
MS, two components were observed with molecular masses of
19.32 kDa (major component) and 19.50 Da (minor component)
(Figure 6A). The mass of the major component was approximately
130 Da less than that predicted from the molecular mass of
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Figure 4 BAY 11-7082 suppresses the LPS- or IL-1-stimulated formation of K63-pUb chains and the DNA damage response
(A and B) The experiment was carried out as in Figure 2, except that the K63-pUb chains formed in response to LPS (A) or IL-1β (B) were captured on Halo-NEMO from 6 mg (RAW cells) or 3 mg
(IL-1R cells) of cell extract protein as described in the Experimental section. The K63-pUb chains were identified by immunoblotting with a specific antibody. Further aliquots of the cell extract were
immunoblotted for IKKβ phosphorylation, p105 phosphorylation and GAPDH as in Figure 2. (C) Indirect immunofluorescence images of U2OS cells transiently expressing GFP–RAP80[1–200]. Cells
were incubated for 1 h with or without BAY 11-7082 (15 μM) and either exposed to ionizing radiation (IR) or not exposed. GFP–RAP80 or γ H2AX were visualized using anti-GFP and anti-γ H2AX
antibodies respectively, and nuclei were stained with DAPI.
the expressed protein. N-terminal sequencing of the preparation
revealed that it lacked the initiator methionine residue, the
sequence starting with the next amino acid, glycine. The absence
of the N-terminal methionine residue accounted for the difference
between the determined and the predicted molecular mass of the
protein. The minor component in the preparation, accounting
for approximately 25% of the total material, was shown by
mass spectrometric analysis of tryptic peptides to be Ubc13 in
which the α-amino group of the N-terminal glycine residue was
gluconoylated, explaining why its molecular mass was 178 Da
greater than that of the major component. N-gluconoylation is
a frequently encountered modification when N-terminally His6-
tagged proteins lose their N-terminal methionine residue to start
with the N-terminal sequence GSSHHHHHH [32].
When Ubc13 was mixed with BAY 11-7082, the molecular
masses of the major and minor components of Ubc13 both
increased by 51 Da, as judged by MALDI–TOF-MS (Figure 6A).
This suggested that the thiol group of the only cysteine residue in
Ubc13 had reacted with BAY 11-7082, forming a covalent bond by
Michael addition at the C3 carbon atom of BAY 11-7082, with the
elimination of 4-methylbenzene-sulfinic acid by the mechanism
depicted in Figure 6(B).
To establish whether the putative covalent adduct in Figure 6(B)
had really been formed, Ubc13 and UbcH7, that had been
inactivated by incubation with BAY 11-7082, were digested
with trypsin and the digest was analysed using an Orbitrap
Classic mass spectrometer (Thermo Scientific). The tryptic digest
of Ubc13 that had been reacted with BAY 11-7082 generated
peptides with molecular masses of 867.5, 1110.6 and 2062.1 Da,
corresponding to the tryptic peptides ICLDILK, ICLDILKDK
and ICLDILKDKWSPALQIR plus 51 Da respectively. MS/MS
analysis of the peptides confirmed that the site of this 51
Da modification was the single cysteine residue in each
peptide. These tryptic peptides contain the only cysteine residue
present in Ubc13 (Cys87), the two longer peptides arising
from partial tryptic cleavage of the lysine-aspartate and lysine-
tryptophan bonds between amino acid residues 92/93 and
94/95 of Ubc13. The unmodified forms of these peptides
with molecular masses of 816.5, 1059.6 and 2011.1 could
not be detected in this experiment, but were identified when
Ubc13 that had not been incubated with BAY 11-7082 was
digested with trypsin. Similarly, tryptic digestion of UbcH7
generated peptides with molecular masses of 1593.8, 1991.0
and 3100.6 Da, corresponding to the molecular masses of the
peptides GQVCLPVISAENWK, GQVCLPVISAENWKPATK
and IYHPNIDEKGQVCLPVISAENWKPATK plus 51 Da
respectively. These tryptic peptides contain the cysteine residue
in UbcH7 (Cys86) that accepts ubiquitin from ubiquitin-loaded
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Figure 5 BAY 11-7082 prevents ubiquitin conjugation to Ubc13 and UbcH7,
but not ubiquitin loading on to the E1 activating enzyme UBE1
UBE1 and ubiquitin (A), UBE1, Ubc13 and ubiquitin (B) or UBE1, UbcH7 and ubiquitin (C) were
incubated for 60 min with the indicated concentrations of BAY 11-7082 and the ubiquitin-loading
reactions were then started by the addition of MgATP. Reactions were terminated by denaturation
in SDS, proteins were subjected to SDS/PAGE and the gels were stained with Coomassie Instant
Blue, followed by destaining in water. Ub, ubiquitin.
UBE1. The two longer peptides arise from partial tryptic cleavage
of the lysine-proline and lysine-glycine peptide bonds between
residues 96/97 and 82/83 of UbcH7. The unmodified forms of
these peptides with molecular masses of 1542.8, 1940.0 and
3049.6 could not be detected after reaction with BAY 11-7082, but
were identified when UbcH7 that had not been exposed to BAY 11-
7082 was digested with trypsin. Taken together, these experiments
establish that BAY 11-7082 inactivates E2-conjugating enzymes
in the way depicted in Figure 6(B).
To further establish the mechanism by which cysteine residues
react with BAY 11-7082, we incubated N-acetyl cysteine with
BAY 11-7082, purified the reaction products as described in
the Experimental section and solved their structures by NMR
(Figure 6C). These experiments established that the reaction
mechanism postulated in Figure 6(B) was correct and also
confirmed that 4-methylbenzene-sulfinic acid had not been
generated in the ion source of the mass spectrometers.
BAY 11-7082 inhibits LUBAC and the IL-1-stimulated formation
of linear-pUb chains
LUBAC is required for the activation of the canonical IKK
complex by the MyD88 signalling network [5,6], raising the
question of whether BAY 11-7082 also suppressed the formation
of linear-pUb chains by HOIP, the catalytic component of
LUBAC. HOIP is an RBR E3 ligase in which ubiquitin is
first transferred from the E2 conjugating enzyme UbcH7 to a
cysteine residue on the E3 ligase before transfer to the substrate
[31]. This suggested that BAY 11-7082 might not only have
suppressed the formation of linear-pUb chains by preventing
the conjugation of ubiquitin to UbcH7, but also the transfer
of ubiquitin from UbcH7 to the active-site cysteine residue on
HOIP [9,33]. We therefore assayed the endogenous LUBAC
activity in RAW 264.7 macrophages after incubating the cells
with and without BAY 11-7082. These experiments showed that
BAY 11-7082 irreversibly inactivated LUBAC in either RAW
264.7 macrophages (Figure 7A) or IL-1R cells (Figure 7B) at
concentrations similar to those that suppress the activation of
IKKβ and TBK1.
LUBAC is thought to be the E3 ligase that generates linear-
pUb chains in cells. Therefore the finding that BAY 11-7082
inactivates LUBAC implied that it should also have prevented
the IL-1-stimulated formation of linear-pUb chains in IL-1R
cells. To investigate whether this was so, we captured the linear-
pUb chains on Halo-NEMO (see the Experimental section) and
identified them by their characteristic electrophoretic mobility
on SDS/PAGE, which differs from K63-pUb oligomers of
equivalent length. These experiments established that BAY
11-7082 completely suppressed the IL-1-stimulated formation
of linear-pUb oligomers comprising two to seven ubiquitin
molecules (Figure 7C). These linear pUb oligomers could be
detected most clearly with the anti-ubiquitin antibody from Enzo
Life Sciences, which we found to be more sensitive than the anti-
ubiquitin antibody from Dako that was used to assay LUBAC
in vitro (Figure 7A). The detection of these small linear-pUb
oligomers additionally required exposure of the immunoblots
for 2 min, compared with the 5–15 s needed to detect the much
longer pUb chains formed in response to IL-1 (compare also
Figures 4 and 7C). Small K63-pUb oligomers were not detected
in these experiments, either because they are not formed or are
not captured by NEMO as efficiently as the small linear-pUb
oligomers, as reported by others [34].
BAY 11-7082 enhances K48-pUb chain formation in cells
by inhibiting the proteasome
The finding that BAY 11-7082 not only prevented the loading of
ubiquitin on to Ubc13 and UbcH7, but also the conjugation
of ubiquitin to many other E2 conjugating enzymes (Supple-
mentary Figure S1) raised the possibility that it might inhibit
every cellular ubiquitylation event. We therefore investigated its
effect on the formation of K48-pUb chains in cells. Interestingly,
BAY 11-7082 did not suppress, but increased the formation of
K48-pUb chains considerably in RAW cells (Figure 8A) and
IL-1R cells (Figure 8B). It further increased the formation of
K48-pUb chains in RAW macrophages that had been elevated by
incubation with the proteasome inhibitor MG132 (Figure 8A), but
had little effect on MG132-stimulated K48-pUb chain formation
in IL-1R cells (Figure 8B). These observations imply that E2
conjugating enzymes that direct the formation of K48-pUb chains
are still active at the concentrations of BAY 11-7082 used in
these experiments. For example, UBE2G1 and UBE2H, which
are reported to direct the formation of K48-pUb chains [35], were
only inhibited partially by BAY 11-7082 under conditions where
the conjugation of ubiquitin to other E2 ligases was abolished.
The observation that BAY 11-7082 enhanced the formation
of K48-pUb chains in cells suggested that this compound might
also inhibit the proteasome. We therefore incubated IL-1R cells
(Figure 8C) and RAW 264.7 macrophages (Figure 8D) in the
absence or presence of BAY 11-7082 or MG132 followed by
immunoblotting of the cell extracts with antibodies that recognize
HIF1α. In normoxic cells, HIF1α is barely detectable because
it undergoes Cullin-2-mediated Lys48-linked polyubiquitylation
followed by proteasomal degradation [36]. We found that BAY
11-7082 induced the appearance of HIF1α similarly to MG132
and polyubiquitylated species of HIF1α could be detected, as
well as unmodified HIF1α (Figures 8C and 8D). These results
are consistent with BAY 11-7082 inhibiting the proteasome.
However, it was possible that BAY 11-7082 had inactivated
UbcH12, the E2 conjugating enzyme for NEDDylation, thereby
preventing the NEDDylation and activation of Cullin 2 [36]. This
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Figure 6 BAY 11-7082 forms a covalent adduct with Ubc13
(A) Ubc13 was incubated without or with BAY 11-7082 and subjected to MALDI–TOF-MS as described in the Experimental section. Incubation with BAY 11-7082 increased the molecular mass of
Ubc13 by 51 Da. (B) Proposed mechanism for how BAY 11-7082 covalently modified Ubc13 and UbcH7 by reacting with the cysteine residue that accepts ubiquitin from UBE1. (C) N-acetyl cysteine
was incubated with BAY 11-7082 and the two products of the reaction, (R,E)-2-acetamido-3-[(2-cyanovinyl)thio]propanoic acid (Compound 1) and 4-methylbenzene-sulfinic acid (Compound 2)
were identified by NMR and MS as described in the Experimental section. Splitting patterns of spectral multiplets are indicated as: s, singlet; d, doublet; dd, doublet of doublets; m, multiplet.
(R,E)-2-acetamido-3-[(2-cyanovinyl)thio]propanoic acid (1): 1H-NMR (500 MHz, [2H4]methanol) δ 7.63 (d, J = 15.8 Hz, 1 H), 5.57 (d, J = 15.8 Hz, 1 H), 4.70 (dd, J = 7.7, 5.0 Hz, 1 H), 3.43 (dd,
J = 14.1, 5.0 Hz, 1H), 3.24 (dd, J = 14.0, 7.8 Hz, 1H), 2.02 (s, 3H). 13C-NMR (126 MHz, CD3OD) δ 173.4, 172.6, 153.9, 118.5, 93.0, 53.1, 34.7, 22.4. HRMS-TOF ( + ): m/z = 215.0499, expected
for C8H11N2O3S 215.0490 [M + H]+ . 4-Methylbenzene-sulfinic acid (2): 1H-NMR (500 MHz, [2H4]methanol) δ 7.61 (m, 2 H), 7.40 (m, 2 H), 2.44 (s, 3 H).13C-NMR (126 MHz, [2H4]methanol) δ
146.5, 143.7, 130.7, 125.7, 21.4. HRMS-TOF ( + ): m/z = 157.0327, expected for C7H9O2S 157.0323 [M + H]+ .
possibility was excluded by showing that the proportion of the
slower migrating NEDDylated form and the faster migrating
de-NEDDylated form of Cullin 2 was not altered by treatment
with BAY 11-7082 or MG132. In contrast, the formation of the
NEDDylated species was blocked by MLN4924 (Figures 8C and
8D), a specific inhibitor of NAE1 [NEDD8 (neural-precursor-cell-
expressed developmentally down-regulated 8)-activating enzyme
E1 subunit 1], the E1 activating enzyme for NEDDylation [23].
These results show that BAY 11-7082 does not inhibit the E1
activating enzyme for NEDD8 or the E2 conjugating enzyme
UbcH12 under the conditions tested and indicate that BAY 11-
7082 is likely to inhibit the proteasome. However, the inhibition
of deubiquitylases by BAY 11-7082 may also contribute to the
enhanced formation of K48-pUb chains. Most deubiquitylases
are cysteine proteinases and we have observed that several of
these enzymes are partially inhibited by BAY 11-7082 in vitro
if thiols are excluded from the assays (A. Knebel, unpublished
work).
NSC697923 inactivates E2 conjugating enzymes and LUBAC
similarly to BAY 11-7082
Recently, the compound NSC697923 was reported to prevent
the survival of DLBCL cell lines, including HBL-1 cells, and
to inhibit Ubc13/UBE2N [37]. We noticed that its structure
had marked similarity to BAY 11-7082. We therefore incubated
Ubc13 with NSC697923 and found that a covalent adduct
was formed with a molecular mass 95 Da greater than that
of Ubc13/UBE2N (Supplementary Figure S2A at http://www.
biochemj.org/bj/451/bj4510427add.htm). This indicated that the
cysteine residue in Ubc13/UBE2N had reacted with NSC697923
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Figure 7 BAY 11-7082 inactivates LUBAC and suppresses the IL-1-
stimulated formation of linear-pUb chains
RAW 264.7 macrophages (A) or IL-1R cells (B) were incubated for 1 h with the indicated
concentrations of BAY 11-7082. The cells were then lysed and LUBAC was immunoprecipitated
(IP) from 1.0 mg of cell extract protein using anti-HOIP as described in the Experimental section.
The immunoprecipitates were washed and LUBAC-catalysed linear-pUb chain formation was
initiated by the addition of UBE1, UbcH7, ubiquitin and MgATP. After incubation for 60 min at
30◦C, the reactions were terminated by denaturation in SDS. Following SDS/PAGE, pUb chain
formation was detected by immunoblotting (IB) with an anti-ubiquitin antibody (Dako). (C) In
lanes 1–6, IL-1R cells were incubated for 1 h with ( + ) or without ( − ) 15 μM BAY 11-7082,
then stimulated for 10 min with ( + ) or without ( − ) 0.5 ng/ml IL-1β . Following cell lysis,
linear-pUb chains and K63-pUb chains were captured from 6 mg of cell extract protein using
Halo-NEMO (see the Experimental section). After denaturation in SDS, the pUb chains were
separated by SDS/PAGE and transferred on to PVDF membranes. The membranes were cut into
two pieces and immunoblotted for 10 s (upper half of gel) or 120 s (lower half of gel) with an
anti-ubiquitin antibody (Enzo Life Sciences). Authentic linear ubiquitin oligomers (lane 7) and
Lys63-linked ubiquitin oligomers (lane 8) were used as markers to demonstrate that the small
ubiquitin oligomers formed in response to IL-1β and captured by Halo-NEMO were linear-pUb
chains and not K63-pUb chains. Ub, ubiquitin.
to form the derivative shown in Supplementary Figure S2(B) and
that, as occurred with BAY 11-7082, 4-methylbenzene-sulfinic
acid had been eliminated. It had been reported that NSC697923
did not inhibit the E2 conjugating enzyme UbcH5c/UBE2D3
[37], but we found that this E2 was inhibited partially under the
conditions we used (Supplementary Figure S1B). NSC697923
also prevented the transfer of ubiquitin to a number of other
Figure 8 BAY 11-7082 enhances the formation of K48-pUb chains and
prevents the degradation of HIF1α by the proteasome
RAW 264.7 macrophages (A) or IL-1R cells (B) were incubated for 1 h without ( − ) or with ( + )
15 μM BAY 11-7082, and then for a further 1 h without ( − ) or with ( + ) the proteasome inhibitor
MG 132. The cells were lysed and aliquots of the cell extract (20 μg of protein) were denatured
in SDS, subjected to SDS/PAGE and immunoblotted with antibodies that recognize K48-pUb
chains specifically. (C and D) RAW macrophages (C) or IL-1R cells (D) were incubated for 2 h
without or with 15 μM BAY 11-7082, 25 μM MG132 or 1 μM MLN4924. The cells were then
lysed in the presence of 50 mM iodoacetamide to inhibit de-ubiquitylases and de-NEDDylases
and immunoblotted with antibodies that recognize HIF1α and Cullin 2, and GAPDH as a loading
control. IB, immunoblot.
E2 conjugating enzymes, including UbcH7/UBE2L3, UBE2D2,
UBE2G1, UBE2G2, UBE2L6, UBE2R2, UBE2S and UBE2T
(Supplementary Figure S1B). However, NSC697923 appears to
be more selective than BAY 11-7082 as a number of other E2
conjugating enzymes were unaffected by this compound (Sup-
plementary Figure S1B). Similar to BAY 11-7082, NSC697923
irreversibly inhibited LUBAC, increased the formation of Lys48-
linked pUb chains and blocked the IL-1-stimulated formation
of K63-pUb chains in IL-1R cells (Supplementary Figure S3
at http://www.biochemj.org/bj/451/bj4510427add.htm). Similar
results were obtained using RAW 264.7 macrophages and LPS as
the stimulus (results not shown).
DISCUSSION
BAY 11-7082 has been reported to induce the necroptotic death of
precursor-B acute lymphoblastic leukaemic blasts (pre-B ALL)
[38] and the death of natural killer/T-cell lymphomas [39]. It
was found to destroy HTLV-1 (human T-cell lymphotropic virus
1) T-cell lines, but not HTLV-1-negative T-cells, and was shown
to induce the apoptosis of primary adult leukaemic cells more
readily than normal peripheral blood mononuclear cells [40]. BAY
11-7082 and the closely related BAY 11-7085 also induced the
apoptosis of colon cancer cells and inhibited tumour implantation
in the liver after the intra-peritoneal delivery of HT-29 colon
cancer cells [41]. These effects have all been attributed to the
inhibition of NF-κB. In the present study we found that BAY
11-7082 and BAY 11-7085 also induced the death of HBL-1
lymphoma cells expressing the MyD88[L265P] mutation, but
other inhibitors of the canonical IKK complex and its activator
TAK1 did not (Figure 1), which suggested that BAY 11-7082
and BAY 11-7085 were exerting their effects on HBL-1 cells by
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alternative/additional mechanisms and led us to investigate what
the mechanism might be.
BAY 11-7085 was originally described as a potent anti-
inflammatory drug, which reduced oedema formation in the
rat carrageenan paw oedema assay and reduced paw swelling
in a rat adjuvant arthritis model [42]. It was also shown to
suppress irreversibly the TNFα (tumour necrosis factor α)-
stimulated phosphorylation of IκBα, and hence the activation
of the transcription factor NF-κB [42]. For these reasons it was
assumed to exert its anti-inflammatory effects by suppressing the
activation of NF-κB. It has been used in more than 350 papers
to implicate the canonical IKK complex and NF-κB in many
cellular events. However, we found that BAY 11-7082 did not
inhibit IKKα, IKKβ or the IKK-related kinases in vitro and nor
did it inhibit the activity or activation of IRAK1 and IRAK4
(Supplementary Table S1 and Figure 3). These observations led
us to discover that BAY 11-7082 prevented the IL-1-stimulated
and LPS-stimulated formation of K63-pUb and linear-pUb chains
by irreversibly inhibiting E2 conjugating enzymes required for
the formation of these pUb chains (Ubc13, UbcH7) and the E3
ubiquitin ligase HOIP, the catalytic component of LUBAC that
directs the formation of linear-pUb chains. The suppression of
K63-pUb chains and/or linear-pUb chains presumably explains
how BAY 11-7082 prevents the activation of the IKK subfamily
of protein kinases by LPS and IL-1.
Although the inhibition of NF-κB may contribute to the
BAY 11-7082/5-induced death of leukaemic and lymphoma
cells, the present study has suggested several other ways in
which these molecules may induce cell death. For example,
we found that BAY 11-7082 is likely to inhibit the proteasome
(Figure 8) and the proteasome inhibitor bortezomib/velcade also
induced the death of HBL-1 cells (Supplementary Figure S4 at
http://www.biochemj.org/bj/451/bj4510427add.htm). Moreover,
BAY 11-7082 prevented the response to DNA damage by
blocking the formation of K63-pUb chains leading to the
gradual accumulation of DNA lesions (Figure 4Cviii) that may
culminate in apoptosis. Finally, BAY 11-7082 inactivated many
E2 conjugating enzymes in vitro (Supplementary Figure S1),
suggesting that the inhibition of multiple ubiquitylation events
may contribute to HBL-1 cell death. The present study has also
established that the recently described compound NSC697923
exerts its effects on DLBCL cell lines, including HBL-1 cells, by
the same mechanism as BAY 11-7082 (Supplementary Figures
S1B, S2 and S3).
Consistent with the findings reported in the present study,
BAY 11-7082 and BAY 11-7085 have been reported to inhibit
the NALP3 inflammasome in macrophages by an NF-κB-
independent mechanism [43]. The NALP3 inflammasome pro-
cesses pro-IL-1β and pro-IL-18 into the active pro-inflammatory
cytokines IL-1β and IL-18 respectively. The anti-inflammatory
effects of these compounds could therefore result from the
combined inhibition of the NALP3 inflammasome, the inhibition
of NF-κB and JNK and other branches of the MyD88 signalling
network. Although BAY 11-7082 was reported to inhibit NALP3
ATPase activity in vitro [43], the way in which this compound
suppresses the processing of pro-IL-1β and pro-IL-18 by the
inflammasome is unclear. An intriguing possibility is that BAY
11-7082 also blocks activation of the inflammasome by targeting
components of the ubiquitin system that affect the NALP3
ATPase.
BAY 11-7085 was found to be as effective as dexamethasone in
reducing paw swelling in a rat model of adjuvant-induced arthritis
when it was injected intraperitoneally once a day at 20 mg/kg [42].
It is remarkable that a compound like BAY 11-7085, which has
such a profound effect on the ubiquitin system, could be used
daily for 2 weeks to reduce inflammation in an animal model of
arthritis, without significant side effects being noted. It will clearly
be of great interest in the future to see whether more specific
inhibitors of LUBAC and particular E2 conjugating enzymes can
be developed, and whether they also show efficacy in the treatment
of inflammatory diseases, as well as lymphomas and other cancers
of immune cells.
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Figure S1 Many E2 conjugating enzymes are inactivated by BAY 11-7082
and NSC697923
The E2 conjugating enzymes (UBE) indicated were incubated for 45 min at 20◦C with UBE1
and ubiquitin in the absence of any thiol and in the absence ( − ) or presence ( + ) of 10 μM
BAY 11-7082 (A) or 20 μM NSC697923 (B). Ubiquitin loading was initiated by the addition of
MgATP and carried out for 10 min at 30◦C as described in the legend to Figure 5 of the main text.
The reactions were terminated in SDS, subjected to SDS/PAGE and the gels were stained with
Coomassie Instant Blue and destained in water. Several E2 ligases, such as UBE2D1, UBE2D2,
EBE2D3, UBE2D4, UBE2Q1 and UBE2Q2, undergo polyubiquitylation during the reaction as
shown by a ladder of bands of decreasing electrophoretic mobility.
1 To whom correspondence should be addressed (email p.cohen@dundee.ac.uk).
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Figure S2 NSC697923 forms a covalent adduct with Ubc13
(A) Ubc13 was incubated without or with NSC697923 and subjected to MALDI–TOF-MS as described in the Experimental section of the main text. Incubation with NSC697923 increased the
molecular mass of Ubc13 by 95 Da. (B) Proposed mechanism for how NSC697923 covalently modifies Ubc13.
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Figure S3 NSC697923 suppresses the IL-1-stimulated formation of
K63-pUb chains in cells, inactivates LUBAC and enhances the formation
of K48-pUb chains
(A) The experiment was carried out as in Figure 4(A) of the main text, except that IL-1R
cells were incubated for 1 h with the indicated concentration of NSC697923. K63-pUb chains
were identified by immunoblotting with a specific antibody. Further aliquots of the cell extract
(20 μg of protein) were immunoblotted for p105 phosphorylation (p-p105) and GAPDH. (B)
IL-1R cells were incubated for 1 h with the indicated concentrations of NSC 697923. The
cells were lysed and LUBAC was immunoprecipitated from 1.0 mg of cell extract protein using
anti-HOIP antibody as described in the Experimental section of the main text. After washing
the immunoprecipitates, the LUBAC-catalysed formation of linear-pUb chains was initiated
by the addition of UBE1, UbcH7, ubiquitin and MgATP. After incubation for 60 min at 30◦C, the
reactions were terminated by denaturation in SDS. Following SDS/PAGE, pUb chain formation
was detected by immunoblotting (IB) with an anti-ubiquitin (Ub) antibody (Dako). (C) IL-1R
cells were incubated for 1 h without ( − ) or with ( + ) 20 μM NSC697923, and then for a
further 1 h without ( − ) or with ( + ) the proteasome inhibitor MG 132. The cells were lysed and
aliquots of the cell extract (20 μg of protein) were denatured in SDS, subjected to SDS/PAGE
and immunoblotted with antibodies that recognize K48-pUb chains specifically.
Figure S4 Bortezomib induces the destruction of HBL-1 cells
HBL-1 cells were incubated in the absence of any inhibitor () or in the presence of 0.1 μM of
the proteasome inhibitor bortezomib () and cell proliferation was monitored as a function of
time. Values are means +− S.D. for three experiments each performed in triplicate.
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Table S1 Effect of BAY 11-7082 on various kinase activities
Assays were performed at 0.1 mM ATP in the absence of any thiol. The results are presented
as the activity in the presence of BAY 11-7082 divided by the activity in the absence of BAY
11-7082 multiplied by 100.
Percentage activity remaining at the indicated BAY 11-7082 concentration
Protein kinase 1 μM 10 μM
IKKα 126 102
IKKβ 96 89
TBK1 98 91
IRAK1 107 113
IRAK4 114 115
TAK1 102 24
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